Pandey Stuti, Tripathi Pragya, Parashar Palak, Maurya Vikas, Malik Md Zubbair, Singh Raja, Yadav Pooja, Tandon Vibha
Department of Chemistry, University of Delhi, Delhi 110007, India.
Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi 110067, India.
ACS Omega. 2022 Jan 10;7(3):2861-2880. doi: 10.1021/acsomega.1c05743. eCollection 2022 Jan 25.
Small molecules that modulate biological functions are targets of modern-day drug discovery efforts. A new series of novel 1-benzo[]imidazoles (BBZs) were designed and synthesized with different functional groups at the phenyl ring and variable lengths of the alkyl chain at the piperazine end as anticancer agents. We identified human topoisomerase I (Hu Topo I) as a probable target of these molecules through a computational study and DNA relaxation assay, a functional assay of the Hu Topo I enzyme. UV absorption, fluorescence, and circular dichroism spectroscopy were used to study interactions between BBZ and DNA. Out of 16 compounds, , , and showed strong binding affinity and thermal stabilization of AT sequence-specific DNA. BBZs were screened against a panel of 60 human cancer cell lines at National Cancer Institute, USA. Most potent molecules , , and showed 50% growth inhibition (GI) in a concentration range from 0.16 to 3.6 μM cancer cells. Moreover, showed 50% inhibition of the relaxation of DNA by Hu Topo I at 16 μM. Furthermore, flow cytometry revealed that , , and cause prominent G2M arrest of cancer cells. In view of the above, we propose that deserves to be further evaluated for its therapeutic use as an anticancer agent.
调节生物功能的小分子是现代药物研发工作的目标。设计并合成了一系列新型的1-苯并咪唑(BBZ),其苯环带有不同官能团,哌嗪端的烷基链长度可变,作为抗癌剂。通过计算研究和DNA松弛测定(一种人拓扑异构酶I(Hu Topo I)酶的功能测定),我们确定Hu Topo I可能是这些分子的靶点。利用紫外吸收、荧光和圆二色光谱研究BBZ与DNA之间的相互作用。在16种化合物中,[具体化合物名称缺失]、[具体化合物名称缺失]和[具体化合物名称缺失]对AT序列特异性DNA表现出强结合亲和力和热稳定性。在美国国立癌症研究所,对BBZ进行了针对60种人类癌细胞系的筛选。最有效的分子[具体化合物名称缺失]、[具体化合物名称缺失]和[具体化合物名称缺失]在0.16至3.6μM的癌细胞浓度范围内显示出50%的生长抑制(GI)。此外,[具体化合物名称缺失]在16μM时对Hu Topo I介导的DNA松弛表现出50%的抑制作用。此外,流式细胞术显示,[具体化合物名称缺失]、[具体化合物名称缺失]和[具体化合物名称缺失]导致癌细胞显著的G2M期阻滞。鉴于上述情况,我们建议[具体化合物名称缺失]作为抗癌剂的治疗用途值得进一步评估。